Tom Little/File PhotoUS supplies of the obesity drug semaglutide finally caught up with the demand, but its availability isn’t necessarily good news for consumers, Wired reported. The drug, typically sold under brand names Wegovy for obesity and Ozempic for diabetes, has rapidly become one of the most widely taken medications in the world, with one survey finding 13% of all Americans have used it. But demand far outstripped supply: It has been on the Food and Drug Administration’s shortage list since 2022, until last week, when it was declared “available.” The decision to remove semaglutide from the list could make it less accessible however, as it also means that the rules around making cheaper, off-brand versions will be tightened up. |